Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of D961H (20 mg Once Daily) Versus Placebo for Prevention of Gastric and/or Duodenal Ulcers Associated With Continuous Low-dose Aspirin (LDA) Use

NCT01069939 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01069939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01069939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of D961H (20 mg Once Daily) Versus Placebo for Prevention of Gastric and/or Duodenal Ulcers Associated With Continuous Low-dose Aspirin (LDA) Use
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2010
Completion date
November 30, 2011
Enrollment
427 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

prevention